Thomas David M, Ballinger Mandy L
The Kinghorn Cancer Centre & Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Recent Results Cancer Res. 2016;205:169-89. doi: 10.1007/978-3-319-29998-3_10.
Sarcomas are rare and heterogeneous diseases that affect a younger population than most epithelial cancers. Epidemiologic studies suggest a strong genetic component to sarcomas, and many familial cancer syndromes have been described, in which sarcomas are a feature. The best known of these are the Li-Fraumeni and retinoblastoma syndromes, study of which has been pivotal to elucidating the molecular basis for the cell response to DNA damage and the cell division. Although much has been learnt about cancer biology from the study of sarcoma families, in general clinical management of increased sarcoma risk has lagged behind other cancer predisposition syndromes. With the advent of genomic tools for genetic testing, it is likely that a substantial fraction of sarcoma patients will be identified as carriers of known risk alleles. The translation of this knowledge into effective risk management programs and cancer treatments will be essential to changes in routine clinical practice.
肉瘤是罕见且异质性的疾病,与大多数上皮癌相比,其发病群体更为年轻。流行病学研究表明肉瘤具有很强的遗传因素,并且已经描述了许多家族性癌症综合征,其中肉瘤是一个特征。其中最著名的是李-佛美尼综合征和视网膜母细胞瘤综合征,对它们的研究对于阐明细胞对DNA损伤的反应和细胞分裂的分子基础至关重要。尽管从肉瘤家族的研究中已经了解了很多癌症生物学知识,但总体而言,肉瘤风险增加的临床管理落后于其他癌症易感性综合征。随着用于基因检测的基因组工具的出现,很可能相当一部分肉瘤患者将被确定为已知风险等位基因的携带者。将这些知识转化为有效的风险管理计划和癌症治疗方法对于改变常规临床实践至关重要。